New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you manage anxiety in patients prior to bone marrow biopsy procedure in the clinic?

1 Answers

Mednet MemberInvited Expert
Hematology · Johns Hopkins University

With the use of the drill procedure for bone marrow biopsies, my experience is that the pain element of this procedure has essentially been eliminated. Prior to this, we offered conscious sedation, when possible, to our patients because of the painful nature of the biopsy procedure, which is not aba...

What is your approach to systemic anticoagulation for patients with hypoalbuminemia and nephrotic syndrome secondary to a non-membranous nephropathy condition?

5
4 Answers

Mednet MemberInvited Expert
Nephrology · Loyola University Health System

Patients with nephrotic syndrome (NS) and hypoalbuminemia have a several-fold higher risk of venous thromboembolism (VTE) than the general population and also a somewhat higher risk of arterial thromboembolism (ATE), such as MI and stroke. This risk seems to be higher in membranous nephropathy (MN) ...

Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?

1
4 Answers

Mednet MemberInvited Expert
Cardiology · Weill Cornell Medical College, Cornell University

I believe that apixaban carries a lower risk of bleeding, with particular reference to GI bleed, when compared to rivaroxaban and dabigatran. This is true in the population of AF patients at large and most probably in frail patients as well.

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you approach the outpatient management of bispecific antibody therapy for hematologic malignancies?

1 Answers

Mednet Member
Medical Oncology · Harvard Medical School

Multiple bispecific antibodies (BsAbs) targeting CD20 on lymphoma cells and CD3 on T-cells are now available in follicular and large B-cell lymphoma. A multi-disciplinary team with knowledge of the different BsAb indications and possible toxicities is an important aspect of safely administering thes...

How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?

1
3 Answers

Mednet Member
Hematology · University of Minnesota

With commercial CD19 CAR-T therapy moving into earlier lines of therapy, post-CAR-T relapses are now more common. There are still many options depending on what first-line/bridging therapy was given, CD19/20/30 expression, and patient preferences. I always get a biopsy if feasible to confirm relapse...

What initial workup do you perform when there is a concern for porphyria?

3
1 Answers

Mednet MemberInvited Expert
Hematology · The Mass General Porphyria Center

This is a terrific question. But a broad question. Porphyria refers to a defect in heme biosynthesis leading to the accumulation of porphyrins and porphyrin precursors. We should remember that there are three general categories of porphyria based on clinical manifestations: acute hepatic porphyria (...

When would you opt for a chemotherapy free approach in the first line treatment for hairy cell leukemia?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Ohio State University

This is an outstanding question and there are a few reasons to consider treatments other than cladribine or a chemotherapy-free approach. I have considered and used alternatives in special situations, mostly those with infections. I will limit this to the treatment of classic hairy cell leukemia as ...

Has your practice changed to PLEX-free initial therapy for iTTP?

1
1 Answers

Mednet MemberInvited Expert
Hematology · University of Rochester School of Medicine and Dentistry

I am not. The reason is that caplacizumab is not on formulary at my institution, and so implementing PLEX rapidly while obtaining caplacizumab (which typically arrives in 24-48 hours) is my current practice. If I had caplacizumab on formulary, I would utilize it as it was utilized in the MAYARI tria...

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

5
2 Answers

Mednet MemberInvited Expert
Infectious Disease · Harbor-UCLA Medical Center

PCV-21 was recently approved by the FDA and supported by ACIP. At this early stage (August 2024), CDC has not finalized guidance on PCV-21, so we do not know how the vaccine schedule will be changed. An important distinction is that PCV-21 covers different serotypes of pneumococcus, as outlined in t...

How do you decide between anticoagulation or portal vein recanalization in a patient with portal vein thrombosis?

1
1 Answers

Mednet MemberInvited Expert
Hepatology · Northwestern

It depends on cirrhotic vs non-cirrhotic. For cirrhotic, best to reference the AASLD 2020 guidance here - Northup et al., PMID 33219529.For non-cirrhotic: important to determine the etiology as well as evaluate for a hypercoagulable state, including checking for JAK2 and CALR.If acute and non-occlus...